James Levine, President and Chief Executive Officer

Janet Roemer, Executive Vice President and Chief Operating Officer

Jeffrey Black, Senior Vice President and Chief Financial Officer

Alex Fitzpatrick, Senior Vice President, General Counsel & Secretary

Ken Barrett, Vice President of Business Development & Strategy

Kevin Bracken, Vice President of Manufacturing

Cate Scanlon, Vice President of Human Resources

Mark Wall, Vice President of R&D Operations

David Weiner, Vice President of R&D Strategy, Innovation & Partnerships

James Levine
President and Chief Executive Officer

James Levine became President, Chief Executive Officer and a member of the Board of Directors of Verenium in April 2011.  He joined Verenium in April 2009 as Executive Vice President and Chief Financial Officer.  Prior to joining Verenium, Mr. Levine held various positions focused on the energy and healthcare industries with the global investment banking and securities firm, Goldman Sachs & Co., where he most recently served as a Managing Director in the Power and Utilities Group in New York. Before that he served as a Managing Director in the Goldman Sachs Energy Group in London and held positions in the Goldman Sachs Healthcare Group in London and New York focused on biotechnology companies. Prior to Goldman Sachs, Mr. Levine held positions with Lehman Brothers, Inc. in New York, and Industrial Economics, Inc. in Cambridge, Massachusetts. Mr. Levine received an M.B.A. degree with a concentration in Finance from the Wharton School of the University of Pennsylvania and a B.A. in Economics from Brandeis University in Waltham, Massachusetts.

 back to top

Janet Roemer
Executive Vice President and Chief Operating Officer

Janet Roemer became Chief Operating Officer of Verenium in July 2010.  She joined Verenium in March 2008 as Executive Vice President of the Specialty Enzymes Business Unit. Prior to joining Verenium, Ms. Roemer held several positions with BP Group, one of the world's largest oil and gas companies. She was Chief of Staff to the CEO of Innovene, a $24 billion petrochemical and refining business within BP Group. Prior to that, Ms. Roemer held executive level roles including chief executive of a $1.7 billion North American chemical business, Vice President of Digital Business, and General Manager of a $700 million global chemical business. Ms. Roemer also held various positions at Amoco Corporation between 1983 and 1999, in sales and marketing management, product management, production planning and logistics, and strategic planning. She began her career as a chemist at National Starch and Chemical. Ms. Roemer received an M.B.A. from the University of Chicago, and a Bachelor's degree in Chemistry from Miami University in Oxford, Ohio.

 back to top

Jeffrey Black
Senior Vice President and Chief Financial Officer

Jeffrey Black became senior Vice President and Chief Financial Officer in April 2011. Mr. Black joined Verenium in 2005 as Chief Accounting Officer. Mr. Black has 20 years in financial management and advisory roles and has served in senior level financial management roles for six publicly-traded companies. Mr. Black's experience includes serving as Executive Director of Accounting and Corporate Controller of Isis Pharmaceuticals, Inc. and Principal and Interim Financial Executive of Regent Pacific Management Corporation, a financial advisory firm through which he served as Vice President of Finance and Corporate Controller of Clarent Corporation and Vice President and Corporate Controller of Accelerated Networks, Inc. Mr. Black is a certified public accountant (inactive) and began his career with Ernst & Young LLP. Mr. Black graduated with a bachelor's degree in business from the University of Arizona in 1991.

 back to top

Alex Fitzpatrick
Senior Vice President, General Counsel & Secretary

Alex Fitzpatrick, Senior Vice President, General Counsel and Secretary, joined Verenium in November 2010.   Prior to joining Verenium, Mr. Fitzpatrick served as Senior Vice President, General Counsel and Secretary of Kintera, Inc, a publicly traded technology company.  Following the sale of Kintera, Mr. Fitzpatrick continued to serve in a similar position for a major division of Blackbaud, Inc.  Previously, Mr. Fitzpatrick was Director of Strategic Transactions for a division of Vivendi Universal SA.  Prior to that, as a member of the business, corporate and technology departments with the law firms Cooley LLP and Latham & Watkins LLP in San Diego, and Rogers & Wells LLP (now Clifford Chance) in London, Mr. Fitzpatrick represented biotech and other technology companies, investment banks and venture capitalists in a variety of transactions including numerous collaborations, mergers and acquisitions, intellectual property matters, licensing and financing activity.  Mr. Fitzpatrick received a B.S. in mathematics from Georgetown University a J.D. from the University of California, Berkeley.

 back to top

Ken Barrett
Vice President, Business Development & Strategy

Ken Barrett joined Verenium in August 2006 as Associate Director of Business Development responsible for supporting the Company's commercialization strategy with a focus on developing internal capabilities and launching new products. In 2008, Mr. Barrett was promoted to Director of Business Development and in 2010 he was promoted to his current position, in which he leads the Company's strategy and business development efforts.  Prior to joining Verenium, Mr. Barrett was a co-Founder and Managing Director of Trident Partners, LLC, a private equity and management firm focused on small and medium sized businesses which differentiated itself by direct involvement in operations and strategy development of its acquisitions.  Before that, Mr. Barrett served as a consultant at Bain & Company developing and applying analytical frameworks and generating insights and results for client businesses.  He began his career at Mitsubishi Motors Corporation in 1989 in Japan. Mr. Barrett received a M.S. in Applied Biosciences from the University of Arizona in Tucson, Arizona, a M.B.A. degree from Harvard Business School in Boston, Massachusetts and a B.A. in Engineering Sciences from Dartmouth College in Hanover, New Hampshire.

 back to top

Kevin Bracken
Vice President, Manufacturing

Kevin Bracken joined Verenium in August 2010 as Vice President of Manufacturing.  Prior to joining Verenium, Mr. Bracken was Vice President of Manufacturing at Vical Incorporated, a developer of biopharmaceutical products, where he was responsible for all manufacturing activities, served on numerous product development, validation and technical teams for new product candidates, and supervised all scale-up and optimization operations for the company.  Before that Mr. Bracken was Vice President of Process Engineering and Manufacturing at Universal Preservation Technologies, Inc., and was Director of Engineering for Molecular Biosystems. Prior to that, he held positions of increasing responsibility in process engineering with Gilead Sciences and Baxter International.  Mr. Bracken began his career as an engineer with DuPont. Mr. Bracken received a B.S. in Chemical Engineering from the University of Delaware and a M.S. in Chemical Engineering from the University of Rochester.

 back to top

Cate Scanlon
Vice President, Human Resources

Catherine Scanlon became Vice President, Human Resources in February 2012. She joined Verenium in September 2007 as Sr. Manager, became Director in August 2010 and head of human resources in March 2011. Prior to joining Verenium, Ms. Scanlon held several positions with increasing responsibility, including Director of Human Resources, at Cambridge Energy Research Associates, Inc. (now a division of IHS, Inc.) a leading energy strategy and consulting firm in Cambridge, Massachusetts. Ms. Scanlon received a Masters in Counseling Psychology from Boston College, Boston, Massachusetts and a Bachelors degree in English from Canisius College, Buffalo, New York. Ms. Scanlon also holds certifications as a Senior Human Resources Professional (SPHR) and a Certified Compensation Professional (CCP).

 back to top

Mark Wall
Vice President, R&D Operations

Mark Wall joined Verenium in 2002, and has served in a variety of roles in R&D including genome sequencing as well as project and technology development in enzymes, biofuels and protein therapeutics. He became Vice President of R&D Operations in August of 2011. Throughout his tenure at Verenium, Dr. Wall has been a member on various coordinating boards which have been responsible for project execution and scientific development, and he was principal investigator on an NIH grant to improve antibody function. Dr. Wall has over 19 years postgraduate experience in structural biology, biophysics and structure-function analysis as well as genomics. Key publications from Dr. Wall have had broad impact and have been cited over 1,570 times. Prior to joining Verenium, Dr. Wall was a Howard Hughes research fellow for his post-doctoral fellowship. Dr. Wall received a Ph.D. from the University of Texas Southwestern Medical Center in Dallas and received a Bachelor of Science in Chemistry from the University of Texas at Austin.

 back to top

David Weiner
Vice President, R&D Strategy, Innovation & Partnerships

David Weiner joined Verenium in 1997 as a Senior Scientist and has held a variety of R&D positions in his 14 years with the Company and played a pivotal role in the development of Verenium's technology platform, product portfolio and pipeline.  He was named Vice President R&D Strategy, Innovation & Partnerships in March 2011. Prior to joining Verenium, Dr. Weiner pursued research fellowships at the Scripps Research Institute in La Jolla, CA and at Amherst College, MA.  He is a frequent speaker at industry conferences, has published over 20 peer-reviewed scientific papers, and is an inventor on over 30 published patent applications.  Dr. Weiner received his Bachelors in Science and his Ph.D. in Chemistry from the University of Leicester in the United Kingdom.

 back to top